NCT01757808View on ClinicalTrials.gov

A Study of Ranolazine Acute Administration and Short Term Administration in Pulmonary Arterial Hypertension

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

Ranolazine

ranolazine sustained release at a dose of 500mg for one month followed by a dose of 1000mg.

DRUG

Placebo

placebo at a dose of 500mg for one month followed by a dose of 1000mg.

Trial Locations (1)

60637

University of Chicago, Chicago

All Listed Sponsors
lead

University of Chicago

OTHER

NCT01757808 - A Study of Ranolazine Acute Administration and Short Term Administration in Pulmonary Arterial Hypertension | Biotech Hunter | Biotech Hunter